Lieff Cabraser Heimann & Bernstein, LLP

For over a decade, Lieff Cabraser has successfully represented patients who took the diet drugs known as fen-phen and suffered serious injuries, including heart valve injuries or developed pulmonary hypertension.

Additional Compensation Available to "Green Forms" Claimants Until 2015

If you suffered valvular heart disease due to Fen Phen and received compensation under the Diet Drugs Settlement, you may be entitled to additional compensation.

For example, if you had heart disease at Level 1 or Level 2 under the settlement and now require heart valve surgery, you may submit a new claim and could be eligible for a recovery of several hundred thousand dollars.

The deadline to submit your new claims varies. For certain patients, it is December 31, 2011. For other patients, it is December 31, 2015.

Video

Contact Lieff Cabraser

Lieff Cabraser attorneys have extensive experience representing clients before the AHP Settlement Trust. We have assisted patients whose heart conditions worsened to a more severe level in obtaining additional compensation for their injuries.

To learn how you can receive the maximum recovery you are entitled to under the Diet Drugs Settlement, please click here to contact a Lieff Cabraser attorney or call us toll-free at 1-800-541-7358 and ask to speak to attorney Fabrice N. Vincent.

We also provide information without charge or obligation on the legal options for patients who have developed valve disease, heart enlargement, atrial fibrillation, pulmonary hypertension and/or who have died from FenPhen/Pondimin/Redux.

Background on Lieff Cabraser's work in Fen Phen (Diet Drugs) Litigation and Settlement

Lieff Cabraser represents individuals pursuing personal injury claims due to injuries from the "Fen-Phen" diet drugs fenfluramine (sold as Pondimin) and/or dexfenfluramine (sold as Redux). We served as counsel for the plaintiff that filed the first nationwide class action lawsuit against the diet drug manufacturers alleging that they had failed to adequately warn physicians and consumers of risks associated with the drugs.

Since the recall was announced in 1997, Lieff Cabraser has represented over 400 persons in individual actions who have suffered heart and/or lung damage, most often consisting of cardiac valve damage and/or Primary Pulmonary Hypertension (PPH) or Pulmonary Arterial Hypertension (PAH), after ingesting Pondimin or Redux.

In In re Diet Drugs (Phentermine | Fenfluramine | Dexfenfluramine) Products Liability Litigation, MDL No. 1203 (E.D. Pa.), the Court appointed Elizabeth J. Cabraser to the Plaintiffs' Management Committee which organized and directed the Fen-Phen diet drugs litigation filed across the nation in federal courts. In August 2000, the Court approved a $4.75 billion settlement offering both medical monitoring relief for persons exposed to the drug and compensation for persons with qualifying damage. Lieff Cabraser also served on the Plaintiffs' Executive Committee in the California Coordinated Proceedings in California state court, and as class counsel in the State of Washington certified medical monitoring action.